In a report released today, Sean Dodge from RBC Capital maintained a Hold rating on GoodRx Holdings (GDRX – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $7.54.
Dodge covers the Healthcare sector, focusing on stocks such as Evolent Health, GoodRx Holdings, and Catalent. According to TipRanks, Dodge has an average return of -5.0% and a 42.30% success rate on recommended stocks.
In addition to RBC Capital, GoodRx Holdings also received a Hold from Morgan Stanley’s Craig Hettenbach in a report issued on March 1. However, on the same day, Guggenheim maintained a Buy rating on GoodRx Holdings (NASDAQ: GDRX).
See the top stocks recommended by analysts >>
GDRX market cap is currently $2.98B and has a P/E ratio of -322.22.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GoodRx Holdings (GDRX) Company Description:
GoodRx Holdings Inc provides digital healthcare platform that provides prescription drugs at affordable prices. The company offers services like diabetes testing, general visits, blood tests, HIV testing, Vitamin D screening, Pregnancy testing, and many more.
Read More on GDRX:
